Post

Horizon doses first participant in Phase I gout therapy trial

The Phase I trial will evaluate the pharmacokinetics, tolerability, pharmacodynamics, and safety of HZN-457.

The Metaverse: Macroeconomic trends

Gaming and social media companies are at the vanguard of metaverse development, but enterprises will lead the charge in the…

Biosimilars hit a turning point as they expand outside oncology

Biosimilar drugs are biological medicines that are extremely similar to another biological medicine that has already been licensed for use.

Health Canada grants CTA authorisation for QurAlis’ ALS therapy

Assessing the safety and tolerability of varying doses of QRL-201 in ALS patients is the primary objective of the trial.

Leading artificial intelligence (AI) companies in clinical trials

Artificial intelligence (AI) is instrumental in solving several key clinical trial challenges. It can help in the synthesis and analysis…

Leading cloud computing companies in clinical trials

Cloud-based clinical trials can reduce the huge expense and long lead times of traditional clinical trials. Clinical data sharing improves…

Leading cybersecurity companies in clinical trials

Clinical trial software is vulnerable to breaches and ransomware attacks, as clinical trials become more decentralised and incorporate the use…

The Brazilian pharma market: Key information and what may change

Brazil has the largest pharmaceutical market in Latin America, and recent political changes have raised speculation about what other changes could be in store. We take a look at the country’s pharma market and explore what could be around the corner in terms of legislation.

Leading Internet of Things (IoT) companies in clinical trials

Internet of Things (IoT) plays a significant role in clinical trials in terms of regulatory authorisations, post-marketing trials, clinical trial…

Regenxbio concludes subject dosing in Phase I/II severe MPS I trial

Assessing the safety of RGX-111 is the primary endpoint of the trial.

BioAge Labs reports positive trial results for the treatment of muscle atrophy

The company plans to begin a Phase II trial in the prevention of ICU diaphragmatic atrophy and critical illness myopathy.

Relmada reports data from trial of REL-1017 for major depressive disorder

The RELIANCE I trial results showed that REL-1017-treated patients had a 15.1 point reduction in the MADRS.

Sitero and CRIO partner to improve patient safety in trials

The collaboration will remove the need for redundant, manual, and error-prone activities across the clinical lifecycle.

Suvoda unveils electronic clinical outcome assessments design toolkit

The toolkit is created to integrate with the Suvoda IRT and eConsent, and also address the historical inadequacies that impact eCOA.

Next on diversity: inclusion of participants with cognitive impairment in clinical trials

Clinical Trials Arena dives into a frequently forgotten aspect of clinical trial diversity: participation of people with cognitive disabilities.